Onderzoeker
Gil Verschelden
- Trefwoorden:Geneeskunde
Affiliaties
- Intensieve geneeskunde (Departement)
Lid
Vanaf1 jan 2024 → Heden - Spoedgevallen & transit (Departement)
Lid
Vanaf1 okt 2023 → 31 dec 2023 - Interne Geneeskunde (Departement)
Lid
Vanaf1 okt 2021 → 30 sep 2023 - Interne Geneeskunde (Departement)
Lid
Vanaf1 aug 2017 → 30 sep 2019 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf1 okt 2015 → 7 sep 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf26 jul 2011 → 24 jun 2015
Publicaties
1 - 9 van 9
- Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools(2023)
Auteurs: Gil Verschelden, Maxim Noeparast, Laura Vandervore, A Stoefs, Margo Olbrecht, Eveline Van Honacker, Katleen Vandamme, Kristof Vandoorslaer, Thomas Demuyser, Denis Pierard, et al.
- Analysis of a Combined HBHA and ESAT-6-Interferon-γ-Release Assay for the Diagnosis of Tuberculous Lymphadenopathies(2023)
Auteurs: Françoise Mascart, Maya Hites, Emmanuelle Watelet, Gil Verschelden, Christelle Meuris, Jean-Luc Doyen, Anne Van Praet, Audrey Godefroid, Emmanuelle Petit, Mahavir Singh, et al.
- Optimization of the Transwell® assay for the analysis of neutrophil chemotaxis using flow cytometry to refine the clinical investigation of immunodeficient patients(2022)
Auteurs: Maïlis Lauwers, Gil Verschelden, Caroline Boero, Manon Baleine, Véronique Kerrels, Brigitte Cantinieaux
- Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy)(2022)
Auteurs: Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, Alpha Diallo, Minh-Patrick Lê, Gilles Peytavin, Thérèse Staub, et al.
Pagina's: 209-221 - Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection(2022)
Auteurs: A Poncelet, Gil Verschelden, Martin Colard, M. Hildebrandt, Nicolas Yin, Charlotte Michel, David Grimaldi, Virginie De Wilde
Pagina's: 253-255 - Presumed Urinary Tract Infection in Patients Admitted with COVID-19: Are We Treating Too Much?(2021)
Auteurs: Johan Van Laethem, Stephanie Wuyts, Jan Pierreux, Lucie Seyler, Gil Verschelden, Thibault Depondt, Annelies Maurits Y Meuwissen, P Lacor, Denis Pierard, Sabine D Allard
- Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID)(2021)
Auteurs: Jozefien Declercq, Karel F A Van Damme, Elisabeth De Leeuw, Bastiaan Maes, Cedric Bosteels, Simon J Tavernier, Stefanie De Buyser, Roos Colman, Maya Hites, Gil Verschelden, et al.
Pagina's: 1427-1438 - Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients(2021)
Auteurs: Gil Verschelden, Maxim Noeparast, Maryam Noparast, Mathijs Goossens, Maïlis Lauwers, Frédéric Cotton, Charlotte Michel, Cleo Goyvaerts, Maya Hites
- Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib(2016)
Auteurs: Maxim Noeparast, Erik Teugels, Philippe Giron, Gil Verschelden, Sylvia De Brakeleer, Lore Decoster, Jacques De Grève
Pagina's: 60094-60108